Kyverna plans to submit mivocabtagene autoleucel to the FDA for approval in the first half of 2026. If approved, it would be ...

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...

For centuries, newer technologies have been met with initial hesitancy — the railroad, the telephone, and, more recently, the electric car. These transformative innovations were first introduced and ...

Potent CAR-T expansion from a single, off-the-shelf infusion without chemotherapy ...

The CAR T-cell therapy market offers significant growth opportunities driven by technological advancements, personalized ...